Edition:
India

Adverum Biotechnologies Inc (ADVM.OQ)

ADVM.OQ on NASDAQ Stock Exchange Global Market

11.72USD
17 Jan 2020
Change (% chg)

$0.02 (+0.17%)
Prev Close
$11.70
Open
$11.94
Day's High
$12.16
Day's Low
$11.46
Volume
257,386
Avg. Vol
549,843
52-wk High
$16.38
52-wk Low
$2.90

Latest Key Developments (Source: Significant Developments)

Adverum Biotechnologies Says Continued Momentum With Optic Trial For Advm-022 Intravitreal Gene Therapy In Wet AMD
Monday, 13 Jan 2020 

Jan 12 (Reuters) - Adverum Biotechnologies Inc ::ADVERUM BIOTECHNOLOGIES REPORTS CONTINUED MOMENTUM WITH OPTIC TRIAL FOR ADVM-022 INTRAVITREAL GENE THERAPY IN WET AMD AND PROVIDES 2020 OUTLOOK.IND APPLICATION PLANNED FOR ADVM-022 IN DIABETIC RETINOPATHY IN 1H20; PATIENT ENROLLMENT TARGETED FOR 2H20.ADVERUM BIOTECHNOLOGIES-OPTIC PHASE 1 TRIAL PROGRESSING WITH PLANS TO COMPLETE COHORT THREE PATIENT DOSING , BEGIN ENROLLMENT IN COHORT FOUR IN 1Q20.  Full Article

Adverum Biotechnologies Reports Q3 Loss Per Share Of $0.25
Friday, 8 Nov 2019 

Nov 7 (Reuters) - Adverum Biotechnologies Inc ::ADVERUM BIOTECHNOLOGIES REPORTS RECENT BUSINESS PROGRESS AND THIRD QUARTER 2019 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.25.Q3 REVENUE $300,000.Q3 EARNINGS PER SHARE ESTIMATE $-0.26 -- REFINITIV IBES DATA.Q3 REVENUE ESTIMATE $177,000 -- REFINITIV IBES DATA.CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS WERE $162.0 MILLION AS OF SEPTEMBER 30, 2019.  Full Article

Adverum Biotechnologies Provides Update On Optic Phase 1 Trial For Advm-022 In Wet AMD
Thursday, 16 May 2019 

May 16 (Reuters) - Adverum Biotechnologies Inc ::ADVERUM BIOTECHNOLOGIES PROVIDES UPDATE ON OPTIC PHASE 1 TRIAL FOR ADVM-022 IN WET AMD.ADVERUM BIOTECHNOLOGIES INC - U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS LIFTED CLINICAL HOLD ON ADVM-022.ADVERUM BIOTECHNOLOGIES - FDA LIFTED CLINICAL HOLD ON SECOND COHORT, ADVM-022 REMAINS ON PARTIAL CLINICAL HOLD FOR DOSING PATIENTS IN THIRD COHORT.ADVERUM BIOTECHNOLOGIES INC - ADVERUM WILL CONTINUE TO WORK CLOSELY WITH FDA TO RESOLVE REMAINING CMC COMMENTS..  Full Article

Adverum Biotechnologies Announces Board Changes
Friday, 3 May 2019 

May 2 (Reuters) - Adverum Biotechnologies Inc ::ADVERUM BIOTECHNOLOGIES ANNOUNCES BOARD CHANGES.ADVERUM BIOTECHNOLOGIES INC - PATRICK MACHADO APPOINTED AS BOARD CHAIR; PAUL CLEVELAND RETIRES FROM BOARD.ADVERUM BIOTECHNOLOGIES INC - INDEPENDENT DIRECTORS REKHA HEMRAJANI, JAMES SCOPA AND MARK LUPHER ADDED TO BOARD.ADVERUM BIOTECHNOLOGIES INC - BOARD CONSISTS OF NINE DIRECTORS, EIGHT OF WHOM ARE INDEPENDENT.  Full Article

Adverum Biotechnologies Q3 Loss Per Share $0.34
Friday, 9 Nov 2018 

Adverum Biotechnologies Inc ::ADVERUM BIOTECHNOLOGIES REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q3 LOSS PER SHARE $0.34.Q3 EARNINGS PER SHARE VIEW $-0.30 -- THOMSON REUTERS I/B/E/S.QTRLY COLLABORATION AND LICENSE REVENUE $833,000 VERSUS $463,000.Q3 REVENUE VIEW $380000.00 -- THOMSON REUTERS I/B/E/S.  Full Article

Adverum Biotechnologies Receives Fast Track Designation For ADVM-022 Gene Therapy For The Treatment Of wAMD
Thursday, 20 Sep 2018 

Sept 19 (Reuters) - Adverum Biotechnologies Inc ::ADVERUM BIOTECHNOLOGIES RECEIVES FAST TRACK DESIGNATION FOR ADVM-022 GENE THERAPY FOR THE TREATMENT OF wAMD.ADVERUM BIOTECHNOLOGIES INC SAYS OPTIC PHASE 1 CLINICAL TRIAL INITIATION EXPECTED IN 4Q18.ADVERUM BIOTECHNOLOGIES - FAST TRACK DESIGNATION INTENDED TO FACILITATE DEVELOPMENT, EXPEDITE REVIEW OF DRUGS AND BIOLOGICS.  Full Article

Adverum Biotechnologies Q4 Loss Per Share $0.32
Wednesday, 7 Mar 2018 

March 6 (Reuters) - Adverum Biotechnologies Inc ::ADVERUM BIOTECHNOLOGIES REPORTS FOURTH QUARTER 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q4 LOSS PER SHARE $0.32.  Full Article

Adverum Biotechnologies Prices $60 Mln Public Offering Of Stock
Thursday, 8 Feb 2018 

Feb 8 (Reuters) - Adverum Biotechnologies Inc ::ADVERUM BIOTECHNOLOGIES ANNOUNCES PRICING OF $60 MILLION PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 8.89 MILLION COMMON SHARES PRICED AT $6.75PER SHARE.PRICING OF AN UNDERWRITTEN PUBLIC OFFERING OF 8.8 MILLION SHARES OF ITS COMMON STOCK AT A PRICE TO PUBLIC OF $6.75 PER SHARE.  Full Article

Adverum Biotechnologies Announces Proposed Public Offering
Thursday, 8 Feb 2018 

Feb 7 (Reuters) - Adverum Biotechnologies Inc ::ADVERUM BIOTECHNOLOGIES ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.ADVERUM BIOTECHNOLOGIES - INTENDS TO GRANT UNDERWRITERS 30-DAY OPTION TO BUY UP TO ADDITIONAL 15% OF SHARES OF COMMON STOCK OFFERED IN PUBLIC OFFERING.  Full Article